Shell Asset Management’s Acadia Pharmaceuticals ACAD Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q3 | $55K | Sell |
2,561
-3,454
| -57% | -$81.7K | 0.01% | 829 |
|
|
2025
Q2 | $130K | Sell |
6,015
-244
| -4% | -$4.54K | ﹤0.01% | 921 |
|
|
2025
Q1 | $104K | Sell |
6,259
-271
| -4% | -$4.92K | ﹤0.01% | 1010 |
|
|
2024
Q4 | $120K | Hold |
6,530
| – | – | 0.01% | 1002 |
|
|
2024
Q3 | $100K | Buy |
+6,530
| New | +$109K | ﹤0.01% | 1051 |
|
|
2024
Q1 | $112K | Buy |
6,904
+2,474
| +56% | +$61.3K | 0.01% | 983 |
|
|
2023
Q4 | $139K | Sell |
4,430
-1,351
| -23% | -$32.3K | 0.01% | 973 |
|
|
2023
Q3 | $120K | Sell |
5,781
-88
| -1% | -$2.39K | 0.01% | 1043 |
|
|
2023
Q2 | $141K | Sell |
5,869
-32
| -0.5% | -$711 | 0.01% | 1032 |
|
|
2023
Q1 | $111K | Sell |
5,901
-20
| -0.3% | -$381 | ﹤0.01% | 1075 |
|
|
2022
Q4 | $94K | Sell |
5,921
-1,152
| -16% | -$18K | ﹤0.01% | 1164 |
|
|
2022
Q3 | $116K | Sell |
7,073
-1,886
| -21% | -$30.5K | ﹤0.01% | 1178 |
|
|
2022
Q2 | $126K | Buy |
8,959
+4,633
| +107% | +$86.5K | ﹤0.01% | 1227 |
|
|
2022
Q1 | $105K | Sell |
4,326
-653
| -13% | -$15.8K | ﹤0.01% | 1290 |
|
|
2021
Q4 | $116K | Sell |
4,979
-82
| -2% | -$1.65K | ﹤0.01% | 1313 |
|
|
2021
Q3 | $84K | Sell |
5,061
-200
| -4% | -$3.85K | ﹤0.01% | 1317 |
|
|
2021
Q2 | $128K | Hold |
5,261
| – | – | ﹤0.01% | 1322 |
|
|
2021
Q1 | $136K | Sell |
5,261
-5,322
| -50% | -$234K | ﹤0.01% | 1230 |
|
|
2020
Q4 | $566K | Sell |
10,583
-2,591
| -20% | -$129K | 0.01% | 744 |
|
|
2020
Q3 | $543K | Hold |
13,174
| – | – | 0.01% | 645 |
|
|
2020
Q2 | $639K | Sell |
13,174
-148
| -1% | -$7.11K | 0.02% | 560 |
|
|
2020
Q1 | $563K | Sell |
13,322
-203
| -2% | -$8.36K | 0.02% | 616 |
|
|
2019
Q4 | $579K | Sell |
13,525
-296
| -2% | -$12.9K | 0.01% | 816 |
|
|
2019
Q3 | $497K | Sell |
13,821
-119
| -0.9% | -$3.61K | 0.01% | 891 |
|
|
2019
Q2 | $373K | Sell |
13,940
-319
| -2% | -$8.15K | 0.01% | 1017 |
|
|
2019
Q1 | $383K | Hold |
14,259
| – | – | 0.01% | 1001 |
|
|
2018
Q4 | $231K | Sell |
14,259
-1,200
| -8% | -$23.3K | 0.01% | 1021 |
|
|
2018
Q3 | $321K | Hold |
15,459
| – | – | 0.01% | 1055 |
|
|
2018
Q2 | $236K | Sell |
15,459
-873
| -5% | -$15.6K | ﹤0.01% | 1047 |
|
|
2018
Q1 | $367K | Hold |
16,332
| – | – | 0.01% | 977 |
|
|
2017
Q4 | $492K | Buy |
+16,332
| New | +$522K | 0.01% | 910 |
|
|
2017
Q3 | – | Sell |
-11,622
| Closed | -$324K | – | 1090 |
|
|
2017
Q2 | $324K | Hold |
11,622
| – | – | 0.01% | 994 |
|
|
2017
Q1 | $400K | Sell |
11,622
-4,988
| -30% | -$176K | 0.01% | 957 |
|
|
2016
Q4 | $479K | Sell |
16,610
-17,034
| -51% | -$451K | 0.01% | 891 |
|
|
2016
Q3 | $1.07M | Buy |
+33,644
| New | +$1.14M | 0.02% | 633 |
|
Other funds holding ACAD
BBA
RI
PAI
B
Shell Asset Management's ACAD Position: Q3 2025 in Review
Shell Asset Management reduced its Acadia Pharmaceuticals (ACAD) stake by 57% in Q3 2025, selling an estimated $81.7K and leaving 2,561 shares worth $55K. The position accounts for 0.01% of the portfolio, ranked #829.
Shell Asset Management first reported a position in ACAD in Q3 2016 and has held it in 35 quarters since. The position peaked at $1.07M in Q3 2016. 334 funds tracked by Wall St. Rank hold ACAD as of Q3 2025.
- Shell Asset Management held 2,561 shares of Acadia Pharmaceuticals worth $55K as of Q3 2025.
- Shell Asset Management sold 3,454 Acadia Pharmaceuticals shares in Q3 2025, an estimated $81.7K.
- Acadia Pharmaceuticals made up 0.01% of Shell Asset Management's portfolio in Q3 2025, its #829 holding.
- Shell Asset Management first reported a position in Acadia Pharmaceuticals in Q3 2016 and has held it in 35 quarters since.
- Shell Asset Management's Acadia Pharmaceuticals position peaked at $1.07M in Q3 2016.
- 334 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q3 2025.
Based on Shell Asset Management's 13F filing for Q3 2025, filed 7 Nov 2025.